Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620020 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 563
- Enrollment target
NCT02620020 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 563 participants.
The verdict
NCT02620020, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 563 participants
- Enrollment target
Study Summary
The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS). Secondary objectives of the study are to evaluate the efficacy of fasinumab compared to placebo as measured by: * Change from baseline in the Roland Morris disability questionnaire (RMDQ) total score * Change from baseline in the Patient Global Assessment (PGA) of Low Back Pain (LBP) score * Change from baseline in the average daily LBPI NRS score
Interventions
- DRUG placebo
- DRUG Fasinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 563 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2017-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620020
The ClinicalTrials.gov registry entry for NCT02620020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 563 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02620020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02620020 about?
NCT02620020 is a clinical study titled "A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain". The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS). Secondary objectives of the study are to evaluate the efficacy of fasinumab compared...
What is the current status of trial NCT02620020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 563 participants. The study started on 2016-01-26. Estimated completion is 2017-09-13.
What interventions are being tested in trial NCT02620020?
The interventions under investigation include: placebo (DRUG), Fasinumab (DRUG).
Who is sponsoring clinical trial NCT02620020?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.